Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

Hepatocellular carcinoma is the most common primary liver cancer and the fourth leading cause of cancer death worldwide. A total of 70−80% of patients are diagnosed at an advanced stage with a dismal prognosis. Sorafenib had been the standard care for almost a decade until 2018 when the Fo...

Full description

Bibliographic Details
Main Authors: Vito Longo, Oronzo Brunetti, Antonio Gnoni, Antonella Licchetta, Sabina Delcuratolo, Riccardo Memeo, Antonio Giovanni Solimando, Antonella Argentiero
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:Medicina
Subjects:
hepatocellular carcinoma
immune checkpoint inhibitors
hcc
pembrolizumab
nivolumab
immune microenvironment
targeted therapies
Online Access:https://www.mdpi.com/1010-660X/55/10/698

Internet

https://www.mdpi.com/1010-660X/55/10/698

Similar Items